€20m Action Tackles Poor Uptake Of Joint HTAs Across Europe; Commission Consultation Nears
Executive Summary
Europe’s EUnetHTA collaboration is working on producing a raft of new joint HTA reports for medical device and drug developers, and it is planning to facilitate 35 early dialogues between HTA bodies and manufacturers. It is also exploring why only a few European countries are making full use of the reports it has produced so far. Meanwhile, the European Commission is gearing up to consult extensively on how to create a sustainable network for HTAs across Europe.
You may also be interested in...
Industry Could Be Made To Pay For Stronger HTA Cooperation in EU
The European Commission wants to strengthen EU cooperation in the area of health technology assessment. Among the options it is considering are mandatory and voluntary participation models… and charging medical device and drug companies fees.
Industry Could Be Made To Pay For Stronger HTA Cooperation in EU
The European Commission wants to strengthen EU cooperation in the area of health technology assessment. Among the options it is considering are mandatory and voluntary participation models… and charging drug companies fees.
'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny
The European Commission is to conduct an analysis of the impact of incentives such as data exclusivity, market exclusivity and patent term extensions on innovation, drug pricing, and access to medicines, including generics. The move was requested by member state health ministers who say they are concerned about cases of 'very high and unsustainable price levels' hindering patient access to effective and affordable medicines.